Comparative in Vitro Activities of New 14-, 15-, and 16-membered Macrolides

Overview

Journal Antimicrob Agents Chemother

Publisher American Society for Microbiology

Specialty Pharmacology

Date 1988 Nov 1

PMID 3252753

Citations 82

Authors

D J Hardy

D M Hensey

J M Beyer

C Vojtko

E J McDonald

P B Fernandes

Affiliations

Soon will be listed here.

Abstract

The in vitro activities of several 14-, 15- and 16-membered macrolides were compared with that of erythromycin. In general, 14-membered macrolides such as erythromycin, clarithromycin, and flurithromycin were more active against streptococci and Bordetella pertussis than was the 15-membered macrolide azithromycin, which was more active than 16-membered macrolides such as miocamycin and rokitamycin. Clarithromycin was the most active compound against Streptococcus pyogenes, pneumococci, Listeria monocytogenes, and Corynebacterium species. Legionella pneumophila was most susceptible to miocamycin, clarithromycin, and rokitamycin. Branhamella catarrhalis, Neisseria gonorrhoeae, and Haemophilus influenzae were most susceptible to azithromycin. Azithromycin and dirithromycin were the most active compounds against Campylobacter jejuni. MICs of 16-membered macrolides for strains expressing inducible-type resistance to erythromycin were less than or equal to 1 microgram/ml, whereas none of the compounds had activity against strains expressing constitutive-type resistance. The MICs of roxithromycin, miocamycin, rokitamycin, and josamycin increased in the presence of human serum, whereas MICs of the other compounds either were unchanged or decreased.

Citing Articles

Comparative bactericidal activity of four macrolides alone and combined with rifampicin or doxycycline against at concentrations achievable in foals.

Huguet A, Gourbeyre O, Bernand A, Philibert C, Bousquet-Melou A, Lallemand E Front Pharmacol. 2024; 15:1458496.

PMID: 39624843 PMC: 11608945. DOI: 10.3389/fphar.2024.1458496.

Immunomodulatory Effects of Macrolides Considering Evidence from Human and Veterinary Medicine.

Blondeau J Microorganisms. 2022; 10(12).

PMID: 36557690 PMC: 9784682. DOI: 10.3390/microorganisms10122438.

Macrolide Resistance in : Current Situation and Future Challenges.

Ivaska L, Barkoff A, Mertsola J, He Q Antibiotics (Basel). 2022; 11(11).

PMID: 36358225 PMC: 9686491. DOI: 10.3390/antibiotics11111570.

Determination of the Postexposure Prophylactic Benefit of Oral Azithromycin and Clarithromycin Against Inhalation Anthrax in Cynomolgus Macaques.

Slay R, Hewitt J, Crumrine M Clin Infect Dis. 2022; 75(Suppl 3):S411-S416.

PMID: 36251550 PMC: 9989359. DOI: 10.1093/cid/ciac569.

PK-PD Modeling and Optimal Dosing Regimen of Acetylkitasamycin against in Piglets.

Huang A, Mao F, Huang L, Xie S, Pan Y, Qu W Antibiotics (Basel). 2022; 11(2).

PMID: 35203885 PMC: 8868236. DOI: 10.3390/antibiotics11020283.

References

Andrews J, Ashby J, Wise R . Factors affecting the in-vitro activity of roxithromycin. J Antimicrob Chemother. 1987; 20 Suppl B:31-7. DOI: 10.1093/jac/20.suppl_b.31. View

Dette G, Knothe H, Koulen G . Comparative in vitro activity, serum binding and binding activity interactions of the macrolides A-56268, RU-28965, erythromycin and josamycin. Drugs Exp Clin Res. 1987; 13(9):567-76. View

Barry A, Jones R, Thornsberry C . In vitro activities of azithromycin (CP 62,993), clarithromycin (A-56268; TE-031), erythromycin, roxithromycin, and clindamycin. Antimicrob Agents Chemother. 1988; 32(5):752-4. PMC: 172265. DOI: 10.1128/AAC.32.5.752. View

Osono T, Oka Y, Watanabe S, OKAMI Y, Umezawa H . A new antibiotic, josamyicn. I. Isolation and physico-chemical characteristics. J Antibiot (Tokyo). 1967; 20(3):174-80. View

Nitta K, Yano K, Miyamoto F, Hasegawa Y, Sato T . A new antibiotic, josamycin. II. Biological studies. J Antibiot (Tokyo). 1967; 20(3):181-7. View

Strausbaugh L, Dilworth J, Gwaltney Jr J, Sande M . In vitro susceptibility studies with josamycin and erythromycin. Antimicrob Agents Chemother. 1976; 9(3):546-8. PMC: 429568. DOI: 10.1128/AAC.9.3.546. View

Kawaharajo K, Sekizawa Y, Inoue M . In vitro and in vivo antibacterial activity of 9,3"-Di-o-acetyl midecamycin (Mom), a new macrolide antibiotic. J Antibiot (Tokyo). 1981; 34(4):436-42. DOI: 10.7164/antibiotics.34.436. View

Sakakibara H, Okekawa O, Fujiwara T, Otani M, Omura S . Acyl derivatives of 16-membered macrolides. I. Synthesis and biological properties of 3"-O-propionylleucomycin A5 (TMS-19-Q). J Antibiot (Tokyo). 1981; 34(8):1001-10. DOI: 10.7164/antibiotics.34.1001. View

Toscano L, Fioriello G, Spagnoli R, Cappelletti L, ZANUSO G . New fluorinated erythromycins obtained by mutasynthesis. J Antibiot (Tokyo). 1983; 36(11):1439-50. DOI: 10.7164/antibiotics.36.1439. View

10.

Morimoto S, Takahashi Y, Watanabe Y, Omura S . Chemical modification of erythromycins. I. Synthesis and antibacterial activity of 6-O-methylerythromycins A. J Antibiot (Tokyo). 1984; 37(2):187-9. DOI: 10.7164/antibiotics.37.187. View

11.

Bornstein N, Roudier C, Fleurette J . Determination of the activity on Legionella of eight macrolides and related agents by comparative testing on three media. J Antimicrob Chemother. 1985; 15(1):17-22. DOI: 10.1093/jac/15.1.17. View

12.

Fallon R, Brown W . In-vitro sensitivity of legionellas, meningococci and mycoplasmas to ciprofloxacin and enoxacin. J Antimicrob Chemother. 1985; 15(6):787-9. DOI: 10.1093/jac/15.6.787. View

13.

Omura S, Sano H, Sunazuka T . Structure activity relationships of spiramycins. J Antimicrob Chemother. 1985; 16 Suppl A:1-11. DOI: 10.1093/jac/16.suppl_a.1. View

14.

Barker J, Farrell I . The effect of charcoal on MICs for Legionella. J Antimicrob Chemother. 1986; 17(1):127. DOI: 10.1093/jac/17.1.127. View

15.

Leblanc D, Inamine J, Lee L . Broad geographical distribution of homologous erythromycin, kanamycin, and streptomycin resistance determinants among group D streptococci of human and animal origin. Antimicrob Agents Chemother. 1986; 29(4):549-55. PMC: 180439. DOI: 10.1128/AAC.29.4.549. View

16.

Chantot J, Bryskier A, Gasc J . Antibacterial activity of roxithromycin: a laboratory evaluation. J Antibiot (Tokyo). 1986; 39(5):660-8. DOI: 10.7164/antibiotics.39.660. View

17.

MALMBORG A . The renaissance of erythromycin. J Antimicrob Chemother. 1986; 18(3):293-6. DOI: 10.1093/jac/18.3.293. View

18.

Fernandes P, Bailer R, Swanson R, Hanson C, McDonald E, Ramer N . In vitro and in vivo evaluation of A-56268 (TE-031), a new macrolide. Antimicrob Agents Chemother. 1986; 30(6):865-73. PMC: 180609. DOI: 10.1128/AAC.30.6.865. View

19.

Jones R, Barry A . The antimicrobial activity of A-56268 (TE-031) and roxithromycin (RU965) against Legionella using broth microdilution method. J Antimicrob Chemother. 1987; 19(6):841-2. DOI: 10.1093/jac/19.6.841. View

20.

Jorgensen J, REDDING J, Maher L, Howell A . Improved medium for antimicrobial susceptibility testing of Haemophilus influenzae. J Clin Microbiol. 1987; 25(11):2105-13. PMC: 269421. DOI: 10.1128/jcm.25.11.2105-2113.1987. View